CN1850130A - Preparation for preventing and treating cardiovascular and cerebrovascular diseases - Google Patents
Preparation for preventing and treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN1850130A CN1850130A CN 200610031271 CN200610031271A CN1850130A CN 1850130 A CN1850130 A CN 1850130A CN 200610031271 CN200610031271 CN 200610031271 CN 200610031271 A CN200610031271 A CN 200610031271A CN 1850130 A CN1850130 A CN 1850130A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lovastatin
- monas cuspurpureus
- cuspurpureus went
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine preparation or food preparation for curing and preventing angicardiopathy and cerbrovascular disease. It is made up by using anka and ginkgo leaf extract as raw material. It can be used for preventing and curing the diseases of coronary heart disease, angina cordis, hypetension and hyperlipemia, etc. and can obtain obvious therapeutic effect.
Description
One, technical field:
The present invention relates to a kind of is the medicine or the food formulation of the treatment that forms of feedstock production and prevention cardiovascular and cerebrovascular disease symptom with Monas cuspurpureus Went and two kinds of materials of Folium Ginkgo extract.
Two, background technology:
The dried bath leaf of Semen Ginkgo leaf system Ginkgoaceae plant Ginkgo biloba, its property sweetness and bitterness is puckery, has the effect that the beneficial heart is received lung, removing dampness antidiarrheal, activating blood circulation to dissipate blood stasis, TONGMAI SHULUO.The Folium Ginkgo extract chemical constituent is complicated, mainly contains effective ingredient such as flavone and Semen Ginkgo lactone.U.S. FDA to the prescription of Folium Ginkgo extract is: general flavone content＞24%, Semen Ginkgo lactone content＞6%.Folium Ginkgo extract has blood vessel dilating, reduces vascular resistance, and blood flow increasing reduces the cyto-architectural damage of perfusion again of acute cerebral ischemia, prevents hypoxic-ischemic and cerebral edema, promotes resuming function of brain cell; Anticoagulant alleviates neuronal damage due to the oxidative stress, promotes the recovery of function of nervous system.
The main functional component of Monas cuspurpureus Went is: lovastatin and gamma-aminobutyric acid.Monas cuspurpureus Went has tangible blood pressure lowering, blood fat reducing, blood sugar reducing function.
Folium Ginkgo extract and Monas cuspurpureus Went are combined into preparation, and both have synergism, make more remarkable effect.
Three, summary of the invention:
The object of the present invention is to provide the medicine or the food formulation of a kind of treatment and prevention cardiovascular and cerebrovascular disease symptom.Preparation is to be the preparation that raw material can be used for the various dosage forms that the different adjuvant of medicine or food is prepared from addition by two kinds of materials of Monas cuspurpureus Went and Folium Ginkgo extract.
Preparation of the present invention is meant that Monas cuspurpureus Went and Folium Ginkgo extract are that raw material adds different adjuvants, is prepared into the various dosage forms that medicine and food can be made.
The raw material Monas cuspurpureus Went can be the natural Monas cuspurpureus Went that contains the main functional component lovastatin of Monas cuspurpureus Went, can be its extract, also contain the chemical substance of the main functional component lovastatin of Monas cuspurpureus Went behind the purification, its main functional component content lovastatin is greater than one thousandth.
The raw material Folium Ginkgo extract can be to contain the extract of Folium Ginkgo extract main component Ginkgo total flavones, the also chemical substance that contains Folium Ginkgo extract main component ginkgetin behind the purification, and its main component Ginkgo total flavones is greater than one of percentage.
Adjuvant is various excipient, filler, correctives, diluent, binding agent, disintegrating agent, lubricant of medicine and food etc.
Preparation of the present invention is meant the preparation of the various dosage forms that medicine and food can be prepared into.For example: various solid preparations, liquid preparation; Oral preparations, ejection preparation, external preparation or the like.
Technical scheme of the present invention is: the preparation of a kind of treatment and prevention cardiovascular and cerebrovascular disease, and it is characterized in that: by Monas cuspurpureus Went and Folium Ginkgo extract is that feedstock production forms,
The percentage by weight of raw material is (in its main functional component):
Monas cuspurpureus Went (lovastatin) 1-99
Folium Ginkgo extract (Ginkgo total flavones) 99-1
The optimum weight percentage ratio of raw material (in its main functional component):
Monas cuspurpureus Went (lovastatin) 20
Folium Ginkgo extract (Ginkgo total flavones) 80.
Adjuvant is various excipient, correctives, diluent, binding agent, disintegrating agent, the lubricant of medicine and food.
Preparation is meant the preparation of the various dosage forms that medicine and food can be prepared into.For example: various solid preparations, liquid preparation; Oral preparations, ejection preparation, external preparation etc.
Preparation of the present invention is prepared from listed corresponding adjuvant percentage by weight by raw material:
(1) oral liquid: water 70-99.9%;
(2) tablet (comprising dispersible tablet, buccal tablet, chewable tablet, sugar pill): filler 30-85%, disintegrating agent 3-15%, binding agent 0.1-3%, lubricant 0.1-5%;
Filler in the tablet is: starch or lactose or microcrystalline Cellulose or mannitol or sucrose or Icing Sugar or inorganic salt, or one or more of pregelatinized Starch etc. bestly are pregelatinized Starch.
Disintegrating agent is in the tablet: crosslinked polyethylene pyrrole network alkane ketone, or carboxymethyl starch sodium, or low substituted hydroxy-propyl pricker dimension is plain, or the cross-linked carboxymethyl pricker is tieed up plain sodium, or dried starch, or the best is the plain mixture (4: 3) of crosslinked polyethylene pyrrole network alkane ketone and low substituted hydroxy-propyl pricker dimension, or above two kinds, three kinds mixture.
Binding agent is in the tablet: the alcoholic solution of concentration 40%-95%, or aqueous solution, or carboxylic propyl group pricker dimension is plain, methyl pricker dimension element, dextrin, ethyl pricker are tieed up, the carboxymethyl pricker is tieed up plain sodium or starch slurry, or the alcoholic solution of polyethylene pyrrole network alkane ketone etc. one or more, the best is 55% alcoholic solution of 2-4% polyethylene pyrrole network alkane ketone.
Lubricant in the tablet is: magnesium stearate, or micropowder silica gel, or Pulvis Talci.
(3) effervescent tablet: organic acid 10-55%, alkaline matter 10-89%;
Organic acid is in the effervescent tablet: citric acid, malic acid, tartaric acid, lactic acid, fumaric acid, or in the adipic acid one or more.
Effervescent tablet neutral and alkali material is: sodium carbonate is or/and sodium bicarbonate.
(4) granule, capsule: several mixture 10-99.9% of more than one of 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, carboxymethyl starch sodium, methyl pricker dimension element, crystallite pricker dimension element, starch, dextrin, sucrose, lactose, steviosin, aspartame, magnesium stearate, sorbitol, maltol, essence etc.:
(5) spray: several mixture 10-99.9% of more than one of propellant, ethanol, 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, carboxymethyl starch sodium, methyl pricker dimension element, crystallite pricker dimension element, starch, dextrin, sucrose, lactose, steviosin, aspartame, magnesium stearate, sorbitol, maltol, essence etc.;
Preparation method of the present invention is:
Get raw material and corresponding auxiliary material according to prescription, adopt traditional preparation production method, make preparation of the present invention.
Get the corresponding adjuvant that raw material adds above-mentioned dosage form, add adjuvant preparation cost invention oral liquid, syrup, solution, Emulsion, drop, tincture, injection, dispersible tablet, tablet, buccal tablet, pill, chew tablet, effervescent tablet, granule, powder, capsule, soft capsule, spray or the like preparation.
The specification of the bottled oral liquid of the present invention can be 10-1000 milliliter/bottle.
Dispersible tablet of the present invention, tablet, buccal tablet, pill, chewable tablet, effervescent tablet specification can be 0.1 gram-10 gram/sheets.
Particulate specification of the present invention is 1 gram-20 gram/bags
Specification soft, hard capsule of the present invention is 0.1 gram-5 gram/grains
The specification of spray of the present invention is 1 gram-500 gram/bottles
Preparation function of the present invention is: blood circulation promoting and blood stasis dispelling, and TONGMAI SHULUO, dilating coronary blood vessel improves myocardial ischemia.Be used for the prevention and the treatment of coronary heart disease, angina pectoris, hyperlipidemia, cerebrovascular disease.
Four, the specific embodiment:
Prescription 1: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 50 grams and 200 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, additional adjuvant is prepared into ten thousand dosage of 10000 dosage to 40000.
Prescription 2: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 12.5 grams and 200 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, be prepared into 10000 to 40000 dosage with corresponding adjuvant.
Prescription 3: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 200 grams and 200 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, be prepared into 10000 to 40000 dosage with corresponding adjuvant.
Prescription 4: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 50 grams and 50 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, be prepared into 10,000 ten thousand to 40,000 ten thousand dosage with corresponding adjuvant.
Prescription 5: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 50 grams and 800 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, be prepared into 10000 to 40000 dosage with corresponding adjuvant.
Prescription 6: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, the equivalent of getting lovastatin and Ginkgo total flavones is respectively 2.5 grams and 200 grams, get the weight of Monas cuspurpureus Went and Folium Ginkgo extract after the calculating, be prepared into 10000 to 40000 dosage with corresponding adjuvant.
Prescription 7: extract Hongqu powder (red colouring agent) and Folium Ginkgo extract, detect the content of lovastatin and Ginkgo total flavones, get the equivalent that cuts down Ta Ting and Ginkgo total flavones and be respectively 50 grams and 4000 grams, the weight of getting Monas cuspurpureus Went and Folium Ginkgo extract after the calculating is prepared into 10000 to 40000 dosage with corresponding adjuvant.
Embodiment 1: get above-mentioned arbitrary prescription, raw material is: Monas cuspurpureus Went is with its extract, Folium Ginkgo extract, add an amount of correctives, add water to 200000 milliliters, stirring shakes up and is that it is that to become 4000 bottles of specifications be 500 milliliters/bottle oral liquid for 10 milliliters/bottle oral liquid or the 10000 bottles of specifications oral liquid that is 20 milliliters/bottle or fill that suspension, fill become 20000 bottles of specifications.10000 to 40000 dosage.
Embodiment 2, get above-mentioned arbitrary prescription, raw material is: Monas cuspurpureus Went is with its extract, Folium Ginkgo extract, add an amount of correctives, add water to 4000000 milliliters, stirring shakes up and is that it is that to become 8000 bottles of specifications be 500 milliliters/bottle oral liquid for 10 milliliters/bottle oral liquid or the 200000 bottles of specifications oral liquid that is 20 milliliters/bottle or fill that suspension, fill become 400000 bottles of specifications.10000 to 40000 dosage.
Embodiment 3, get above-mentioned arbitrary prescription, raw material is: the natural Hongqu powder (red colouring agent) of Monas cuspurpureus Went, select for use lovastatin content greater than 10/1000ths Monas cuspurpureus Went, Folium Ginkgo extract, select for use Ginkgo total flavones greater than 20 percent Folium Ginkgo extract, powder essence, add an amount of correctives, add above-mentioned additive of tablet disintegrating agent 4500-22500 gram, binding agent 150-4500 gram, lubricant 150-7500 gram, add filler to gross weight 150000 grams, mix, tabletting becomes the tablet of 200,000 0.75 gram/sheets or 400,000 0.375 gram/sheets or 300,000 0.5 gram/sheets or 150,000 1 gram/sheets or 100,000 1.5 gram/sheets or 50,000 3 gram/sheets, dispersible tablet, buccal tablet, chew tablet, ball.10000 to 40000 dosage
Embodiment 4, get above-mentioned arbitrary prescription, raw material is: the natural Hongqu powder (red colouring agent) of Monas cuspurpureus Went, and select for use lovastatin content greater than 10/1000ths Monas cuspurpureus Went; Folium Ginkgo extract selects for use Ginkgo total flavones greater than 20 percent Folium Ginkgo extract; Powder essence, add an amount of correctives, add above-mentioned additive of tablet disintegrating agent 2250-11250 gram, binding agent 75-2250 gram, lubricant 75-3750 gram, add filler to gross weight 75000 grams, mix, tabletting becomes tablet, dispersible tablet, buccal tablet, chew tablet, the ball of 100,000 0.75 gram/sheets or 200,000 0.375 gram/sheets or 150,000 0.5 gram/sheets or 75,000 1 gram/sheets or 50,000 1.5 gram/sheets or 25,000 3 gram/sheets.10000 to 40000 dosage.
Embodiment 5, get above-mentioned arbitrary prescription, raw material is: the natural Hongqu powder (red colouring agent) of Monas cuspurpureus Went, and select for use lovastatin content greater than 10/1000ths Monas cuspurpureus Went; Folium Ginkgo extract selects for use Ginkgo total flavones greater than 20 percent Folium Ginkgo extract; Powder essence, add an amount of correctives, add above-mentioned effervescent tablet adjuvant organic acid 1500-82500 gram, add alkaline matter to gross weight 150000 grams, mix, tabletting becomes the effervescent tablet of 150,000 1 gram/sheets or 300,000 0.5 gram/sheets or 75,000 2 gram/sheets or 50,000 3 gram/sheets or 30,000 5 gram/sheets.10000 to 40000 dosage.
Embodiment 6, get above-mentioned arbitrary prescription, raw material is: the natural Hongqu powder (red colouring agent) of Monas cuspurpureus Went, and select for use lovastatin content greater than 10/1000ths Monas cuspurpureus Went; Folium Ginkgo extract selects for use Ginkgo total flavones greater than 20 percent Folium Ginkgo extract; Powder essence adds an amount of correctives, adds above-mentioned granule adjuvant to 75000 gram or 100000 grams or 150000 grams, and mix homogeneously is granulated, and packing, is packaged into the granule of 5 gram/bags or 10 gram/bags or 15 gram/bags.10000 to 40000 dosage.
Embodiment 7, get above-mentioned arbitrary prescription, raw material is: the natural Hongqu powder (red colouring agent) of Monas cuspurpureus Went, and select for use lovastatin content greater than 10/1000ths Monas cuspurpureus Went; Folium Ginkgo extract selects for use Ginkgo total flavones greater than 20 percent Folium Ginkgo extract; Powder essence adds an amount of correctives, adds above-mentioned granule adjuvant to 50000 gram or 75000 grams or 100000 grams, and mix homogeneously is granulated, and the fill capsule, makes the capsule of 0.25 gram/grain or 0.5 gram/grain or 0.75 gram/grain or 1 gram/grain.10000 to 40000 dosage.
Claims (7)
1, the preparation of a kind of treatment and prevention cardiovascular and cerebrovascular disease, it is characterized in that: by Monas cuspurpureus Went and Folium Ginkgo extract is that feedstock production forms,
The percentage by weight of raw material is (in its main functional component):
Monas cuspurpureus Went (lovastatin) 1-99
Folium Ginkgo extract (Ginkgo total flavones) 99-1
The optimum weight percentage ratio of raw material (in its main functional component):
Monas cuspurpureus Went (lovastatin) 20
Folium Ginkgo extract (Ginkgo total flavones) 80.
2, the preparation of a kind of treatment according to claim 1 and prevention cardiovascular and cerebrovascular disease, it is characterized in that: the preparation method of preparation is: choose raw material Monas cuspurpureus Went (lovastatin) and Semen Ginkgo extrac (Ginkgo total flavones) and adopt traditional preparation production method, add corresponding auxiliary material, be prepared into oral liquid, syrup, solution, Emulsion, drop, tincture, injection, dispersible tablet, tablet, buccal tablet, pill, chew tablet, effervescent tablet, granule, powder, capsule, soft capsule, spray or the like preparation.
3, the preparation of a kind of treatment according to claim 1 and 2 and prevention cardiovascular and cerebrovascular disease, it is characterized in that: Monas cuspurpureus Went (lovastatin) is prepared into oral liquid with the water of Semen Ginkgo extrac (Ginkgo total flavones) raw material weight and 70-99.9%.
4, the preparation of a kind of treatment according to claim 1 and 2 and prevention cardiovascular and cerebrovascular disease, it is characterized in that: Monas cuspurpureus Went (lovastatin) is prepared into tablet with Semen Ginkgo extrac (Ginkgo total flavones) raw material weight and filler 30-85%, disintegrating agent 3-15%, binding agent 0.1-3%, lubricant 0.1-5%.
5, the preparation of a kind of treatment according to claim 1 and 2 and prevention cardiovascular and cerebrovascular disease, it is characterized in that: Monas cuspurpureus Went (lovastatin) and Semen Ginkgo extrac (Ginkgo total flavones) raw material weight and the organic acid of 10-55% and the alkaline matter of 10-80% are prepared into effervescent tablet.
6, the preparation of a kind of treatment according to claim 1 and 2 and prevention cardiovascular and cerebrovascular disease is characterized in that: several mixture 10-99.9% of more than one of Monas cuspurpureus Went (lovastatin) and Semen Ginkgo extrac (Ginkgo total flavones) raw material weight and 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, carboxymethyl starch sodium, methyl pricker dimension element, crystallite pricker dimension element, starch, dextrin, sucrose, lactose, steviosin, aspartame, magnesium stearate, sorbitol, maltol, essence etc. make granule, capsule.
7, the preparation of a kind of treatment according to claim 1 and 2 and prevention cardiovascular and cerebrovascular disease is characterized in that: several mixture 10-99.9% of more than one of Monas cuspurpureus Went (lovastatin) and Semen Ginkgo extrac (Ginkgo total flavones) raw material weight and propellant, ethanol, 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, carboxymethyl starch sodium, methyl pricker dimension element, crystallite pricker dimension element, starch, dextrin, sucrose, lactose, steviosin, aspartame, magnesium stearate, sorbitol, maltol, essence etc. make spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610031271 CN1850130A (en) | 2006-02-21 | 2006-02-21 | Preparation for preventing and treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610031271 CN1850130A (en) | 2006-02-21 | 2006-02-21 | Preparation for preventing and treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1850130A true CN1850130A (en) | 2006-10-25 |
Family
ID=37131642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610031271 Pending CN1850130A (en) | 2006-02-21 | 2006-02-21 | Preparation for preventing and treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1850130A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940608A (en) * | 2010-08-31 | 2011-01-12 | 晨光生物科技集团天津有限公司 | Compound red yeast capsule |
| CN101850039B (en) * | 2009-10-16 | 2012-06-27 | 北京同仁堂健康药业股份有限公司 | Composition with auxiliary lipid-lowering function |
| CN104840800A (en) * | 2015-06-08 | 2015-08-19 | 福州乾正药业有限公司 | Composition of bamboo leaf flavonoid and gamma-aminobutyric acid as well as preparation method and applications thereof |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
| CN105596836A (en) * | 2016-01-22 | 2016-05-25 | 杨晓虹 | Hypolipidemic Allium cepa and Ginkgo biloba composition |
| CN107455742A (en) * | 2017-08-09 | 2017-12-12 | 吉林青晨药业有限公司 | A kind of preparation method with auxiliary lipid-lowering function product |
| CN107550950A (en) * | 2017-10-18 | 2018-01-09 | 朗致集团万荣药业有限公司 | A kind of gingko leaf preparation for treating hypertension and its production and use |
| CN108294308A (en) * | 2018-01-17 | 2018-07-20 | 上海茂久中医药科技有限公司 | A kind of white flower loropetalum chinense health products and preparation method thereof |
-
2006
- 2006-02-21 CN CN 200610031271 patent/CN1850130A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850039B (en) * | 2009-10-16 | 2012-06-27 | 北京同仁堂健康药业股份有限公司 | Composition with auxiliary lipid-lowering function |
| CN101940608A (en) * | 2010-08-31 | 2011-01-12 | 晨光生物科技集团天津有限公司 | Compound red yeast capsule |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
| CN104840800A (en) * | 2015-06-08 | 2015-08-19 | 福州乾正药业有限公司 | Composition of bamboo leaf flavonoid and gamma-aminobutyric acid as well as preparation method and applications thereof |
| CN104840800B (en) * | 2015-06-08 | 2018-05-22 | 福州乾正药业有限公司 | Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application |
| CN105596836A (en) * | 2016-01-22 | 2016-05-25 | 杨晓虹 | Hypolipidemic Allium cepa and Ginkgo biloba composition |
| CN105596836B (en) * | 2016-01-22 | 2019-05-21 | 杨晓虹 | A kind of onion compositions extracted from gingko biloba leaves with effect for reducing blood fat |
| CN107455742A (en) * | 2017-08-09 | 2017-12-12 | 吉林青晨药业有限公司 | A kind of preparation method with auxiliary lipid-lowering function product |
| CN107550950A (en) * | 2017-10-18 | 2018-01-09 | 朗致集团万荣药业有限公司 | A kind of gingko leaf preparation for treating hypertension and its production and use |
| CN108294308A (en) * | 2018-01-17 | 2018-07-20 | 上海茂久中医药科技有限公司 | A kind of white flower loropetalum chinense health products and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1850130A (en) | Preparation for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1850064A (en) | Preparation for relieving stress symptom | |
| CN1886147A (en) | Compositions for the treatment of affections of the oral cavity and upper respiratory tract | |
| CN1813827A (en) | Sea-buckthorn chewing tablet and its preparation | |
| CN1742741A (en) | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof | |
| CN1989960A (en) | Andrographolide dispersed tablet | |
| CN1215071C (en) | Erigeron ester B and its preparation method as well as application in pharmacy | |
| KR101201549B1 (en) | Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN1193763C (en) | Rhodiola total tanning matter extract and use for preparing medicine for curing senile dementia | |
| CN104840962A (en) | Pharmaceutical composition for improving complications of high-fat and high-sugar diet and application thereof | |
| CN1193769C (en) | Health-care food with sobering function | |
| CN1899329A (en) | Medicinal composition with blood fat reducing function | |
| CN101032506A (en) | Chinese traditional medicine composition for hemangiectasis | |
| CN1302774C (en) | Efferverscent tablets containing troxerutin and their preparation | |
| CN1965878A (en) | Pharmaceutical composition containing aceglutamide and safflower effective ingredients and formulation thereof | |
| CN1640439A (en) | Method for preparing oral tablet | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN1799578A (en) | Effervescence tablet with sowthistle tasselflower herb and spreading hedryotis herb and method for preparing the same | |
| CN103156816A (en) | Almotriptan drug absorbed through mouth mucosa | |
| CN1990012A (en) | Three-yellow dispersed tablet | |
| CN1511540A (en) | Use of scutellarin in preparing medicine for treating or preventing stomatocace | |
| CN1742793A (en) | Medicine composition and use thereof | |
| CN101073622A (en) | Chewing tablet for preventing cervicitis and its production | |
| CN1883535A (en) | A pharmaceutical composition containing rhodiola root, its preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20061025 |